APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Phase 1 study evaluating the safety and efficacy of APR-548 in combination with Azacitidine
for the treatment of TP53-Mutant Myelodysplastic Syndromes.